R, packages (e.g. PowerTOST) and regulatory issues (e.g.FDA) [🇷 for BE/BA]

posted by Jérôme Martin  – France, 2013-03-19 18:42 (4415 d 15:59 ago) – Posting: # 10238
Views: 14,155

(edited on 2013-03-20 15:42)

I’m preparing a clinical ANDA BE study for the company I work with and for that purpose I’m using R and the package PowerTOST (I’m computing power and sample size and also I use CVfromCI and CVpooled). I plan to perform both the statistical analysis plan (SAP) and the data analysis.

I’m regarding regulatory issues (FDA mainly and/or EMA) and I’m asking if using R and dedicated package (especially PowerTOST) has already be done and accepted at this stage (clinical ANDA)? If it’s routinely done by other statisticians? If R and this package are known from regulators?

In any cases, did you have advice how to manage those regulatory issues (special letter to regulators? presentation of software or data?...) for a clinical ANDA BE trial with R and packages such as PowerTOST?

I’m aware that FDA made recent clear statement about statistical software, but it’s to have your opinions and feedback.

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,671 registered users;
26 visitors (0 registered, 26 guests [including 9 identified bots]).
Forum time: 11:41 CEST (Europe/Vienna)

The combination of some data and an aching desire
for an answer does not ensure that a reasonable answer
can be extracted from a given body of data.    John W. Tukey

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5